Wen Tian1,2, Xinguo Jiang1,2, Yon K Sung1,2, Eric Shuffle1,2, Ting-Hsuan Wu2, Peter N Kao2, Allen B Tu1,2, Peter Dorfmüller3,4,5, Aiqin Cao2, Lingli Wang2, Gongyong Peng1,2,6, Yesl Kim1,2, Patrick Zhang1,2, James Chappell2, Shravani Pasupneti1,2, Petra Dahms1,2, Peter Maguire2, Hassan Chaib2, Roham Zamanian2, Marc Peters-Golden7, Michael P Snyder2, Norbert F Voelkel8, Marc Humbert3,4,9, Marlene Rabinovitch2, Mark R Nicolls1,2. 1. Veterans Affairs Palo Alto Health Care System, CA (W.T, X.J., Y.K.S., E.S., A.B.T., G.P., Y.K., P.Z., S.P., P.D., M.R.N.). 2. Stanford University School of Medicine, CA (W.T., X.J., Y.K.S., E.S., T.H.W., P.N.K., A.B.T., A.C., L.W., G.P., Y.K., P.Z., J.C., S.P., P.D., P.M., H.C., R.Z., M.P.S., M.R., M.R.N.). 3. Faculté de Médecine, Université Paris-Sud and Université Paris-Saclay, Le Kremlin-Bicêtre, France (P.D., M.H.). 4. Institut National de la Sante Et de la Recherche Medicale UMR_S 999, Le Plessis-Robinson, France (P.D., M.H.). 5. Pathology Department, Hôpital Marie Lannelongue, Le Plessis-Robinson, Paris, France (P.D.). 6. State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, China (G.P.). 7. University of Michigan Health System, Ann Arbor (M.P.G.). 8. Free University Medical Center Amsterdam, the Netherlands (N.F.V.). 9. AP-HP, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire Sévère, Department Hospitalo-Universitaire Thorax Innovation, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France (M.H.).
Abstract
BACKGROUND: Bmpr2 (bone morphogenetic protein receptor 2) mutations are critical risk factors for hereditary pulmonary arterial hypertension (PAH) with approximately 20% of carriers developing disease. There is an unmet medical need to understand how environmental factors, such as inflammation, render Bmpr2 mutants susceptible to PAH. Overexpressing 5-LO (5-lipoxygenase) provokes lung inflammation and transient PAH in Bmpr2+/- mice. Accordingly, 5-LO and its metabolite, leukotriene B4, are candidates for the second hit. The purpose of this study was to determine how 5-LO-mediated pulmonary inflammation synergized with phenotypically silent Bmpr2 defects to elicit significant pulmonary vascular disease in rats. METHODS: Monoallelic Bmpr2 mutant rats were generated and found phenotypically normal for up to 1 year of observation. To evaluate whether a second hit would elicit disease, animals were exposed to 5-LO-expressing adenovirus, monocrotaline, SU5416, SU5416 with chronic hypoxia, or chronic hypoxia alone. Bmpr2-mutant hereditary PAH patient samples were assessed for neointimal 5-LO expression. Pulmonary artery endothelial cells with impaired BMPR2 signaling were exposed to increased 5-LO-mediated inflammation and were assessed for phenotypic and transcriptomic changes. RESULTS: Lung inflammation, induced by intratracheal delivery of 5-LO-expressing adenovirus, elicited severe PAH with intimal remodeling in Bmpr2+/- rats but not in their wild-type littermates. Neointimal lesions in the diseased Bmpr2+/- rats gained endogenous 5-LO expression associated with elevated leukotriene B4 biosynthesis. Bmpr2-mutant hereditary PAH patients similarly expressed 5-LO in the neointimal cells. In vitro, BMPR2 deficiency, compounded by 5-LO-mediated inflammation, generated apoptosis-resistant and proliferative pulmonary artery endothelial cells with mesenchymal characteristics. These transformed cells expressed nuclear envelope-localized 5-LO consistent with induced leukotriene B4 production, as well as a transcriptomic signature similar to clinical disease, including upregulated nuclear factor Kappa B subunit (NF-κB), interleukin-6, and transforming growth factor beta (TGF-β) signaling pathways. The reversal of PAH and vasculopathy in Bmpr2 mutants by TGF-β antagonism suggests that TGF-β is critical for neointimal transformation. CONCLUSIONS: In a new 2-hit model of disease, lung inflammation induced severe PAH pathology in Bmpr2+/- rats. Endothelial transformation required the activation of canonical and noncanonical TGF-β signaling pathways and was characterized by 5-LO nuclear envelope translocation with enhanced leukotriene B4 production. This study offers an explanation of how an environmental injury unleashes the destructive potential of an otherwise silent genetic mutation.
BACKGROUND:Bmpr2 (bone morphogenetic protein receptor 2) mutations are critical risk factors for hereditary pulmonary arterial hypertension (PAH) with approximately 20% of carriers developing disease. There is an unmet medical need to understand how environmental factors, such as inflammation, render Bmpr2 mutants susceptible to PAH. Overexpressing 5-LO (5-lipoxygenase) provokes lung inflammation and transient PAH in Bmpr2+/- mice. Accordingly, 5-LO and its metabolite, leukotriene B4, are candidates for the second hit. The purpose of this study was to determine how 5-LO-mediated pulmonary inflammation synergized with phenotypically silent Bmpr2 defects to elicit significant pulmonary vascular disease in rats. METHODS: Monoallelic Bmpr2 mutant rats were generated and found phenotypically normal for up to 1 year of observation. To evaluate whether a second hit would elicit disease, animals were exposed to 5-LO-expressing adenovirus, monocrotaline, SU5416, SU5416 with chronic hypoxia, or chronic hypoxia alone. Bmpr2-mutant hereditary PAHpatient samples were assessed for neointimal 5-LO expression. Pulmonary artery endothelial cells with impaired BMPR2 signaling were exposed to increased 5-LO-mediated inflammation and were assessed for phenotypic and transcriptomic changes. RESULTS:Lung inflammation, induced by intratracheal delivery of 5-LO-expressing adenovirus, elicited severe PAH with intimal remodeling in Bmpr2+/- rats but not in their wild-type littermates. Neointimal lesions in the diseased Bmpr2+/- rats gained endogenous 5-LO expression associated with elevated leukotriene B4 biosynthesis. Bmpr2-mutant hereditary PAHpatients similarly expressed 5-LO in the neointimal cells. In vitro, BMPR2deficiency, compounded by 5-LO-mediated inflammation, generated apoptosis-resistant and proliferative pulmonary artery endothelial cells with mesenchymal characteristics. These transformed cells expressed nuclear envelope-localized 5-LO consistent with induced leukotriene B4 production, as well as a transcriptomic signature similar to clinical disease, including upregulated nuclear factor Kappa B subunit (NF-κB), interleukin-6, and transforming growth factor beta (TGF-β) signaling pathways. The reversal of PAH and vasculopathy in Bmpr2 mutants by TGF-β antagonism suggests that TGF-β is critical for neointimal transformation. CONCLUSIONS: In a new 2-hit model of disease, lung inflammation induced severe PAH pathology in Bmpr2+/- rats. Endothelial transformation required the activation of canonical and noncanonical TGF-β signaling pathways and was characterized by 5-LO nuclear envelope translocation with enhanced leukotriene B4 production. This study offers an explanation of how an environmental injury unleashes the destructive potential of an otherwise silent genetic mutation.
Authors: Krystyna Teichert-Kuliszewska; Michael J B Kutryk; Michael A Kuliszewski; Golnaz Karoubi; David W Courtman; Liana Zucco; John Granton; Duncan J Stewart Journal: Circ Res Date: 2005-12-15 Impact factor: 17.367
Authors: Lina Qiao; Toshihiko Nishimura; Lingfang Shi; Dane Sessions; Ama Thrasher; James R Trudell; Gerald J Berry; Ronald G Pearl; Peter N Kao Journal: Circulation Date: 2013-11-07 Impact factor: 29.690
Authors: Rajkumar Savai; Hamza M Al-Tamari; Daniel Sedding; Baktybek Kojonazarov; Christian Muecke; Rebecca Teske; Mario R Capecchi; Norbert Weissmann; Friedrich Grimminger; Werner Seeger; Ralph Theo Schermuly; Soni Savai Pullamsetti Journal: Nat Med Date: 2014-10-26 Impact factor: 53.440
Authors: Frédéric Perros; Peter Dorfmüller; David Montani; Hamida Hammad; Wim Waelput; Barbara Girerd; Nicolas Raymond; Olaf Mercier; Sacha Mussot; Sylvia Cohen-Kaminsky; Marc Humbert; Bart N Lambrecht Journal: Am J Respir Crit Care Med Date: 2011-11-22 Impact factor: 21.405
Authors: Nicholas W Morrell; Micheala A Aldred; Wendy K Chung; C Gregory Elliott; William C Nichols; Florent Soubrier; Richard C Trembath; James E Loyd Journal: Eur Respir J Date: 2019-01-24 Impact factor: 16.671
Authors: Emilia M Swietlik; Matina Prapa; Jennifer M Martin; Divya Pandya; Kathryn Auckland; Nicholas W Morrell; Stefan Gräf Journal: Genes (Basel) Date: 2020-11-26 Impact factor: 4.096
Authors: Jan K Hennigs; Aiqin Cao; Caiyun G Li; Minyi Shi; Julia Mienert; Kazuya Miyagawa; Jakob Körbelin; David P Marciano; Pin-I Chen; Matthew Roughley; Matthew V Elliott; Rebecca L Harper; Matthew A Bill; James Chappell; Jan-Renier Moonen; Isabel Diebold; Lingli Wang; Michael P Snyder; Marlene Rabinovitch Journal: Circ Res Date: 2020-12-16 Impact factor: 17.367
Authors: Mengyun Lu; Li-Yuan Chen; Salina Gairhe; Adrien J Mazer; Stasia A Anderson; Jasmine N H Nelson; Audrey Noguchi; Mohammad Abdul Hai Siddique; Edward J Dougherty; Yvette Zou; Kathryn A Johnston; Zu-Xi Yu; Honghui Wang; Shuibang Wang; Junfeng Sun; Steven B Solomon; Rebecca R Vanderpool; Michael A Solomon; Robert L Danner; Jason M Elinoff Journal: Am J Physiol Lung Cell Mol Physiol Date: 2022-01-19 Impact factor: 5.464
Authors: Bradley A Maron; Steven H Abman; C Greg Elliott; Robert P Frantz; Rachel K Hopper; Evelyn M Horn; Mark R Nicolls; Oksana A Shlobin; Sanjiv J Shah; Gabor Kovacs; Horst Olschewski; Erika B Rosenzweig Journal: Am J Respir Crit Care Med Date: 2021-06-15 Impact factor: 30.528
Authors: Wen Tian; Xinguo Jiang; Dongeon Kim; Torrey Guan; Mark R Nicolls; Stanley G Rockson Journal: Front Pharmacol Date: 2020-08-19 Impact factor: 5.810